Abbott Abbokinase Use Should Be Limited Due To Infection Risks From Donors
Executive Summary
Abbott's Abbokinase should be limited to patients who specifically require the thrombolytic agent, FDA's Center for Biologics Evaluation & Research declared in a Jan. 25 letter to healthcare providers.